<DOC>
	<DOCNO>NCT02152956</DOCNO>
	<brief_summary>The primary goal Phase 1 , dose-escalation study , determine maximum tolerate dose level MGD006 patient AML MDS whose disease expect benefit cytotoxic chemotherapy . Studies also do see drug act body ( pharmacokinetics [ PK ] , pharmacodynamics ) evaluate potential anti-tumor activity MGD006 .</brief_summary>
	<brief_title>Safety Study MGD006 Relapsed/Refractory Acute Myeloid Leukemia ( AML ) Intermediate-2/High Risk MDS</brief_title>
	<detailed_description>Open-label , multi-dose , single-arm , multi-center , Phase 1 , dose-escalation study define maximum tolerate dose schedule ( MTDS ) , describe preliminarily safety , assess PK , immunogenicity , immunomodulatory activity , potential anti-tumor activity MGD006 patient AML MDS whose disease expect benefit cytotoxic chemotherapy . This study design three segment : Single Patient Dose Escalation Segment , follow Multi-Patient Dose Escalation Segment MTDS Expansion Cohort Segment . The Multi-Patient Dose Escalation Segment employ classical 3+3 scheme examine series increase dose escalation cohorts patient either AML MDS . Patients enrol one two available dose schedule . Once MTDS establish , cohort patient treat dose/schedule low dose , expand addition 2 cohort 24 patient ( 1 cohort AML 1 cohort MDS ) increase safety experience fully evaluate PK , pharmacodynamics , activity MGD006 . In segment study , patient benefit MGD006 treatment , continue meet eligibility , may continue treatment Cycles 2 beyond .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Confirmed diagnosis primary secondary AML [ subtype except acute promyelocytic leukemia ( APL ) ] accord World Health Organization ( WHO ) classification MDS International Prognostic Scoring System ( IPSS ) risk category Intermediate 2 High Risk Patients AML must unlikely benefit cytotoxic chemotherapy define one follow criterion : leukemia refractory ≥ 2 induction attempt , leukemia 1st relapse initial CR duration &lt; 6 month , leukemia 1st relapse follow ≥ 1 unsuccessful salvage attempt , leukemia 2nd high relapse , prior treatment failure least two cycle hypomethylating agent . Patients MDS must experience treatment failure least one cycle hypomethylating therapy induction therapy ≥ 10 % bone marrow blast Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Life expectancy least 4 week Peripheral blast count &lt; /= 20,000/mm3 time initiation infusion Cycle 1 Day 1 Acceptable laboratory parameter adequate organ reserve Adult ( ≥ 18 year old ) Prior history allogeneic stem cell transplantation Prior treatment antiCD123directed agent Need concurrent cytoreductive chemotherapy Any prior history suspect current autoimmune disorder ( exception vitiligo , resolve childhood atopic dermatitis , prior Grave 's disease euthyroid clinically laboratory test ) Second primary malignancy require active therapy . Adjuvant hormonal therapy allow . Previous treatment radiotherapy immunotherapeutic agent 4 week prior study drug administration ( Cycle 1 Day 1 ) Previous treatment investigational agent 4 week prior study drug administration ( Cycle 1 Day 1 ) Requirement , time study entry , concurrent steroid &gt; 10 mg/day oral prednisone equivalent , except steroid inhaler , nasal spray ophthalmic solution Use immunosuppressant medication 2 week prior study drug administration ( Cycle 1 Day 1 ) Use granulocyte colony stimulate granulocytemacrophage colony stimulate factor 2 week prior study drug administration ( Cycle 1 Day 1 ) Known central nervous system ( CNS ) leukemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>leukemia</keyword>
	<keyword>myelogenous</keyword>
	<keyword>myeloid</keyword>
	<keyword>refractory</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic</keyword>
</DOC>